Replies to post #102205 on Avid Bioservices Inc (CDMO)

[freethemice]

Mojojojo,
I'll send them to you. The "high" and "low" refer to the amount of the receptor proteins CD163 and CD204
that were detected on the surface of the tumor samples. A high amount of either of those two proteins is associated
with the M2-type macrophage. In both of these two studies the patients had mostly earlier stage pancreatic cancer
that was removed by surgery and tumor tissue samples stored for later. It was thought that the surgery might
cure them, but the survival curves show the cancer came back over time except for about 20-30% who had survived for 5 years.
So this is a retrospective look at the patients and an attempt to understand what factors were present that
distinguished long-term survivors from those who were not.
The details are that CD204 (SR-A) is a class A scavenger receptor, and CD163 (MR) is a mannose receptor.

[dia76ca]

That is a great chart mojo! And as you say it shows that Bavi INCREASES the amount of M1 macrophages by four fold compared to the amount seen in a normal tumour enviornment. But it also DECREASES the amount of M2 macrophages four fold.

So if we think of this as a football game prior to Bavi the pro-cancer team had 9 players against the 7 anti-cancer players. No wonder the cancer was winning.

After Bavi enters the fray the pro-cancer team is reduced to 2 players while the anti-cancer team is increased to 14. Now the MOS is doubled...and with better combinations cancer may even be wiped out!

[Fire Fox]

The pre-clinical research poster related to the Company's Oct 31, 2012 PR doesn't just "imply" that Bavi increases M1 polarization, it actually states this as a fact. See notes under the Bavi MOA image at the bottom left of this poster:

http://www.peregrineinc.com/images/stories/pdfs/sitc_2012.pdf

Another interesting aspect of the left image in the lower left corner of this poster is that it shows the PD-1 and CTLA-4 markers (which got so much attention and major press coverage at ASCCO this year) as being essentially "down stream" MOAs that stimulate the T-cells as apposed to Bavi's more "upstream" MOA the affects the core of the tumor's immuno-therapeutic stimulatory environment.